NCT05427071 Magnetic Marker Localization for Occult Breast Cancer and Target Axillary Dissection in Node-positive Breast Cancer Post-neoadjuvant Chemotherapy
| NCT ID | NCT05427071 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The University of Hong Kong |
| Condition | Breast Neoplasm |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2020-10-15 |
| Primary Completion | 2023-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2020-10-15 with a primary completion date of 2023-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The use of neoadjuvant chemotherapy in breast cancer is expanding in the recent decade. Patients with good response to neoadjuvant chemotherapy could benefit from de-escalation of breast and axilla operation. However, breast tumor and involved axillary lymph node should be marked before the commencement of chemotherapy. This could facilitate subsequent operative planning and intraoperative assessment of disease response. This study aims to evaluate the feasibility of magnetic marker localization for non-palpable breast cancer and targeted axillary dissection in patients with node-positive breast cancer following neoadjuvant therapy
Eligibility Criteria
Inclusion Criteria: * All patients with cT1-3N1 invasive ductal carcinoma planned for neoadjuvant chemotherapy and/or target therapy * mentally competent to give informed consent * Agreed to proceed with curative operation after chemotherapy and tentatively keen for breast conservative surgery and targeted axillary dissection after neoadjuvant chemotherapy * Radiologically 1-3 ipsilateral axillary lymph node metastases confirmed by cytology or biopsy Exclusion Criteria: * Presence of distant metastasis, inflammatory breast cancers, multi-centric breast cancers * History of previous ipsilateral axillary surgery or irradiation * Hypersensitivity to dextran compounds or iron * Iron overload disease * Pregnant or lactating patients * Patients with pacemaker or other implantable metallic devices in chest wall or prosthesis in shoulder * Mentally incompetent patients
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05427071 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Breast Neoplasm. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05427071 currently recruiting?
Yes, NCT05427071 is actively recruiting participants. Contact the research team at vivian27@hku.hk for enrollment information.
Where is the NCT05427071 trial being conducted?
This trial is being conducted at Hong Kong, Hong Kong.
Who is sponsoring the NCT05427071 clinical trial?
NCT05427071 is sponsored by The University of Hong Kong. The trial plans to enroll 30 participants.